AstraZeneca/Oxford said this week it would assess why its vaccine candidate generated better efficacy at a lower dose. The statement came as the British-Swedish drug maker AstraZeneca started rolling submission of data to regulators across the world, while also battling perception about the varied efficacy data from the trial of the vaccine developed jointly with the University of Oxford.from International-News-Economic Times https://ift.tt/3mb6cnV
via IFTTT
0 comments:
Post a Comment